Immunogenicity and Safety of 2 Schedules of ALVAC-HIV vCP1452 in Chronically HIV-Infected Patients

NCT00219362 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

65

Enrollment

OTHER

Sponsor class

Conditions

HIV Infection

Interventions

BIOLOGICAL: one injection of vCP1452 at W0, W4, W8 and W20
BIOLOGICAL: one injection of vCP1452 at W4, W8 and W20
BIOLOGICAL: one injection of placebo at W0, W4, W8, W20 or at W4, W8,W20

Sponsor

Objectif Recherche Vaccins SIDA